Loading
Extensive Stage Small Cell Lung Cancer / Atezolizumab / Valemetostat · Phase 1 Trial
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 dose-escalation registration for a planned study combining valemetostat with atezolizumab in extensive-stage small-cell lung cancer. The primary aim is to identify the recommended Phase 2 dose based on safety and tolerability in 24 estimated participants. No results are yet reported in this registry record.
Phase 1, Interventional, Single Group, Open label, Treatment purpose. Extensive-stage Small-cell Lung Cancer; age from 18 Years. Intervention: Valemetostat in Combination With Atezolizumab. n = 24. 7 sites: United States.
This is a Phase 1 dose-escalation registration for a planned study combining valemetostat with atezolizumab in extensive-stage small-cell lung cancer. The primary aim is to identify the recommended Phase 2 dose based on safety and tolerability in 24 estimated participants. No results are yet reported in this registry record.
This is a registry record; no efficacy, safety, or tolerability results are reported. Follow-up duration and specific safety endpoints are not detailed beyond the primary outcome statement.
This early-phase trial cannot yet inform clinical practice; results are needed to establish whether the dose and regimen warrant Phase 2 evaluation.
Phase 1 dose-escalation study with planned enrollment of 24 participants; designed to establish safety and recommended Phase 2 dose, not to demonstrate efficacy or clinical benefit.
As stated by the source record.
Quoted from the source exactly as published.
This early-phase trial cannot yet inform clinical practice; results are needed to establish whether the dose and regimen warrant Phase 2 evaluation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06807632). This is a study registration, not published results. Lead sponsor: Memorial Sloan Kettering Cancer Center. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 24 participants (ESTIMATED). Conditions: Extensive-stage Small-cell Lung Cancer. Interventions: DRUG: Valemetostat; DRUG: Atezolizumab. Primary outcome measures: Determine Phase II dose (RP2D) , 1 year. Brief summary: This study will test whether valemetostat in combination with atezolizumab is a safe treatment that causes few or mild side effects in people with extensive-stage small cell lung cancer (SCLC). The researchers will test different doses of valemetostat to find the highest dose that causes few or mild side effects in participants. After the dose is found, researchers will test it in a new group of participants to learn more about the safety of the study treatment and see if it is an effective treatment for extensive-stage SCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.